16 June 2026
Brain Tumour Support has welcomed the powerful and emotive discussions that took place in Parliament yesterday (Monday 15 June), as the urgent need for greater investment in brain cancer research and treatment was debated. Securing this debate was a notable…
Read
31 March 2026
At Brain Tumour Support, we have been closely following developments around Vorasidenib, a targeted therapy that has shown promise for people living with certain types of low-grade glioma. So we are delighted to share today’s final decision by the National…
Read
10 March 2026
We are delighted to share that the Scottish Medicines Consortium (SMC) has approved Vorasidenib (Voranigo) for patients aged 12 and over with IDH-mutant low-grade gliomas, including grade 2 astrocytomas and oligodendrogliomas. This marks an important milestone for patients, families and…
Read
13 January 2026
We know that many people in our community are eagerly anticipating NICE’s decision on NHS funding for Vorasidenib. Yesterday, 12 January, it was announced that the appraisal for the drug has been paused, at the request of the drug’s manufacturer,…
Read
19 December 2025
Hope for our community as NIHR funding is invested to establish a new Brain Tumour Research Consortium The National Institute for Health and Care Research (NIHR) has today announced key funding which is a significant move towards better treatments and…
Read
14 November 2025
Bristol-based neuropathologist Professor Kathreena Kurian, who lost her husband Gerard to a brain tumour, is leading a national campaign to end postcode inequalities in brain tumour care with a newly released study into molecular and genetic testing of brain tumour patients….
Read
19 October 2025
Liam Vincent-Kilbride was diagnosed with a grade 2 glioma, and following surgery in October 2024 was offered to be part of the Early Access Program, taking Vorasidenib. After 10 months on the drug, he shared his experience and reaction in…
Read
7 October 2025
Our Head of Support Services, Lucy Wilkinson, explains the significance to glioblastoma patients of a clinical trial planned for next year. A ground breaking gene therapy clinical trial for glioblastoma is expected to launch in early 2026, offering new hope…
Read
24 April 2024
Novartis announced today that the National Institute for Health and Care Excellence (NICE) has published its Final Draft Guidance NICE has recommended the combination therapy of dabrafenib (Finlee®) and trametinib (Spexotras®) for the treatment of children with low-grade glioma (LGG)…
Read